Copyright
©The Author(s) 2024.
World J Clin Oncol. Jan 24, 2024; 15(1): 45-61
Published online Jan 24, 2024. doi: 10.5306/wjco.v15.i1.45
Published online Jan 24, 2024. doi: 10.5306/wjco.v15.i1.45
Characteristics | Low expression of HSPA4 | High expression of HSPA4 | P value |
n | 269 | 270 | |
Pathologic T stage | 0.141 | ||
T1 | 99 (18.5) | 77 (14.4) | |
T2 | 137 (25.6) | 155 (28.9) | |
T3 & T4 | 33 (6.2) | 35 (6.5) | |
Pathologic N stage | 0.028 | ||
N0 | 189 (36.1) | 161 (30.8) | |
N1 | 41 (7.8) | 56 (10.7) | |
N2 & N3 | 31 (5.9) | 45 (8.6) | |
Pathologic stage | 0.012 | ||
Stage I | 163 (30.7) | 133 (25) | |
Stage II | 58 (10.9) | 67 (12.6) | |
Stage III & Stage IV | 43 (8.1) | 67 (12.6) | |
Gender | 0.410 | ||
Female | 149 (27.6) | 140 (26) | |
Male | 120 (22.3) | 130 (24.1) | |
Primary therapy outcome | < 0.001 | ||
PD | 22 (4.9) | 49 (10.9) | |
SD & PR | 22 (4.9) | 22 (4.9) | |
CR | 186 (41.4) | 148 (33) | |
OS event | 0.002 | ||
Alive | 190 (35.3) | 157 (29.1) | |
Dead | 79 (14.7) | 113 (21) |
Characteristics | Total (N) | Univariate analysis | Multivariate analysis | ||
Hazard ratio (95%CI) | P value | Hazard ratio (95%CI) | P value | ||
Pathologic T stage | 527 | ||||
T1 | 176 | Reference | Reference | ||
T2 | 285 | 1.507 (1.059-2.146) | 0.023 | 1.086 (0.726-1.624) | 0.687 |
T3 & T4 | 66 | 3.095 (1.967-4.868) | < 0.001 | 1.571 (0.827-2.984) | 0.168 |
Pathologic N stage | 514 | ||||
N0 | 345 | Reference | Reference | ||
N1 | 96 | 2.293 (1.632-3.221) | < 0.001 | 1.293 (0.653-2.560) | 0.461 |
N2 & N3 | 73 | 2.993 (2.057-4.354) | < 0.001 | 1.774 (0.906-3.471) | 0.094 |
Pathologic stage | 522 | ||||
Stage I | 292 | Reference | Reference | ||
Stage II & stage III & stage IV | 230 | 2.889 (2.141-3.897) | < 0.001 | 1.587 (0.789-3.193) | 0.195 |
Age | 520 | ||||
≤ 65 | 257 | Reference | |||
> 65 | 263 | 1.216 (0.910-1.625) | 0.186 | ||
Gender | 530 | ||||
Female | 283 | Reference | |||
Male | 247 | 1.087 (0.816-1.448) | 0.569 | ||
Number pack years smoked | 363 | ||||
< 40 | 183 | Reference | |||
≥ 40 | 180 | 1.073 (0.753-1.528) | 0.697 | ||
HSPA4 | 530 | ||||
Low | 266 | Reference | Reference | ||
High | 264 | 1.476 (1.104-1.972) | 0.009 | 1.356 (0.967-1.901) | 0.078 |
- Citation: Wu X, Yang SY, Zhang YH, Fang JZ, Wang S, Xu ZW, Zhang XJ. Prognostic and immunological roles of heat shock protein A4 in lung adenocarcinoma. World J Clin Oncol 2024; 15(1): 45-61
- URL: https://www.wjgnet.com/2218-4333/full/v15/i1/45.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i1.45